Daily Ards Research Analysis
Three studies advance understanding and management of acute lung injury/ARDS: a mechanistic discovery of spleen-derived erythroblast-like Ter-cells that limit injury via artemin, identification of extracellular histone H4 as an endothelial-activating DAMP driving ARDS severity, and validation of the PALBI liver function grade as a prognostic marker for 30-day mortality in ARDS. Together they illuminate cross-organ crosstalk, endothelial pathobiology, and pragmatic risk stratification.
Summary
Three studies advance understanding and management of acute lung injury/ARDS: a mechanistic discovery of spleen-derived erythroblast-like Ter-cells that limit injury via artemin, identification of extracellular histone H4 as an endothelial-activating DAMP driving ARDS severity, and validation of the PALBI liver function grade as a prognostic marker for 30-day mortality in ARDS. Together they illuminate cross-organ crosstalk, endothelial pathobiology, and pragmatic risk stratification.
Research Themes
- Cross-organ immuno-hematologic regulation of lung injury
- Endothelial activation and DAMPs in ARDS pathogenesis
- Prognostic stratification using liver function indices in ARDS
Selected Articles
1. Inflammation-induced Generation of Splenic Erythroblast-like Ter-Cells Inhibits the Progression of Acute Lung Injury via Artemin.
This mechanistic study identifies a previously unrecognized spleen-derived erythroblast-like population (Ter-cells) originating from megakaryocyte-erythroid progenitors that restrains acute lung injury progression via artemin signaling. It reframes ARDS pathobiology by implicating nonleukocyte cells from a distal organ in modulating lung injury.
Impact: Reveals a novel nonleukocyte cellular axis and a druggable mediator (artemin) that regulate ALI/ARDS progression, opening avenues for cell- or cytokine-based therapies.
Clinical Implications: While preclinical, artemin-Ter-cell biology suggests potential biomarkers and therapeutic strategies to limit lung injury progression; future translation could inform early intervention in ARDS.
Key Findings
- Inflammation induces a spleen-derived erythroblast-like Ter-119+ population (Ter-cells) from megakaryocyte-erythroid progenitors.
- Ter-cells inhibit the progression of acute lung injury via an artemin-dependent mechanism.
- Nonleukocyte cells from a distal organ (spleen) contribute to ALI/ARDS pathobiology.
Methodological Strengths
- In vivo mechanistic interrogation linking a defined cell population to ALI progression
- Identification of a specific mediator (artemin) connecting Ter-cells to functional protection
Limitations
- Preclinical findings without human validation
- Details on experimental models and translational dosing are not provided in the abstract
Future Directions: Validate Ter-cells and artemin signaling in human ALI/ARDS cohorts; explore therapeutic augmentation or ex vivo expansion strategies; delineate upstream triggers and trafficking.
Identifying inflammation-induced leukocyte subsets and their derived circulating factors has been instrumental in understanding the progression of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Nevertheless, how primary inflammation-induced nonleukocyte populations in distal organs contribute to ALI/ARDS remains poorly defined. Here, we report one population of erythroblast-like cells (Ter-cells) deriving from megakaryocyte-erythroid progenitor cells with a unique Ter-119
2. By activating endothelium histone H4 mediates oleic acid-induced acute respiratory distress syndrome.
Extracellular histone H4 rises in plasma and BALF after OA challenge, correlating with ARDS severity, and directly activates endothelium (HS degradation, vWF release, P-selectin translocation, VE-cadherin loss). Anti-H4 mitigates edema and mortality, while TLRs and calcium mediate endothelial activation, positioning H4 as a pro-inflammatory/pro-thrombotic DAMP in ARDS.
Impact: Pinpoints histone H4 as a targetable DAMP that drives endothelial injury and mortality in ARDS models, offering a mechanistic rationale for anti-histone or endothelium-stabilizing therapies.
Clinical Implications: Suggests potential for anti-H4 strategies or measurement of circulating histones as biomarkers to guide endothelial-protective interventions in severe lung injury.
Key Findings
- Extracellular histone H4 increases in plasma and BALF after OA, correlating with ARDS severity.
- Anti-H4 antibody protects against pulmonary edema and death; H4 pretreatment worsens outcomes.
- H4 activates endothelium (HS degradation, vWF release, P-selectin translocation, VE-cadherin reduction) via TLRs and calcium, enabling neutrophil activation.
Methodological Strengths
- Multiple complementary readouts (blood gases, edema, survival, endothelial markers) in vivo
- Mechanistic blockade with anti-H4 and pathway probing (TLRs, calcium)
Limitations
- Oleic acid model may not generalize to all ARDS etiologies
- No human validation or clinical biomarker thresholds provided
Future Directions: Assess circulating histone H4 as a prognostic biomarker in human ARDS; test anti-histone or endothelial-stabilizing agents in diverse injury models and early-phase trials.
OBJECTIVE: This study investigated pathogenic role and mechanism of extracellular histone H4 during oleic acid (OA)-induced acute respiratory distress syndrome (ARDS). METHODS: ARDS was induced by intravenous injection of OA in mice, and evaluated by blood gas, pathological analysis, lung edema, and survival rate. Heparan sulfate (HS) degradation was evaluated using immunofluorescence and flow cytometry. The released von Willebrand factor (vWF) was measured u
3. Association Between Platelet-Albumin-Bilirubin Grade and the 30-Day Mortality in Patients with Acute Respiratory Distress Syndrome: Evidence from the MIMIC-IV Database.
In 2,841 ICU patients with ARDS from MIMIC-IV, higher PALBI grade independently predicted increased 30-day mortality (adjusted HR 1.55), with stronger effects in older, male, and non-sepsis/pneumonia/COPD subgroups. PALBI may aid pragmatic risk stratification and short-term prognostic counseling.
Impact: Leverages a large, well-characterized ICU database to establish a simple liver function-based index as an ARDS mortality predictor, enabling immediate clinical application and hypothesis generation.
Clinical Implications: Consider incorporating PALBI into early ARDS risk stratification to identify high-risk patients for closer monitoring, resource allocation, and tailored supportive strategies.
Key Findings
- Among 2,841 ARDS patients, 30-day mortality was 24.74%; higher PALBI grade predicted increased mortality (adjusted HR 1.55, 95% CI 1.05–2.29).
- Associations were stronger in patients aged ≥65 years (HR 2.30), males (HR 2.10), and those without sepsis, pneumonia, or COPD.
- Findings support PALBI as a practical tool for short-term risk stratification in ARDS.
Methodological Strengths
- Large sample size with robust multivariable Cox modeling
- Pre-specified subgroup analyses enhancing interpretability
Limitations
- Retrospective single-database design with potential residual confounding
- Lack of external validation and calibration for clinical implementation
Future Directions: Prospective validation of PALBI-based risk models across centers; assess additive value versus established scores; develop decision thresholds to guide interventions.
BACKGROUND: The platelet-albumin-bilirubin (PALBI) grade is a comprehensive assessment index of liver function. Liver dysfunction is a key determinant of the pathogenesis and resolution of acute respiratory distress syndrome (ARDS), which affects the prognosis of patients. AIMS: To evaluate the association of PALBI grade with the risk of 30-day mortality in patients with ARDS. STUDY DESIGN: Retrospective cohort study. METHODS: Univariate and multivariate Cox proportional hazards models were used to evaluate the association between PALBI grade and the 30-day mortality in patients with ARDS; results were described as hazard ratios (HRs) and 95% confidence intervals (CIs). This association was further assessed by subgroup analyses stratified based on age, sex, and complications. RESULTS: A total of 2,841 patients with ARDS were included, of whom, 703 (24.74%) died within 30 days. After adjusting all covariates, a higher PALBI grade was associated with higher odds of 30-day mortality (HR: 1.55, 95% CI: 1.05-2.29). High PALBI grade was related to higher odds of 30-day mortality in patients with ARDS aged ≥ 65 years (HR: 2.30, 95% CI: 1.06-5.01), males (HR: 2.10, 95% CI: 1.29-3.44), without sepsis (HR: 1.71, 95% CI: 1.11-2.64), without pneumonia (HR: 1.86, 95% CI: 1.19-2.91), and without any history of chronic obstructive pulmonary disease (HR: 1.93, 95% CI: 1.28-2.91). CONCLUSION: The PALBI grade was positively associated with 30-day mortality in patients with ARDS. The present study provides a reference for risk stratification management of patients with ARDS to improve short-term prognosis.